| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Wu Yunqing, Cui Shilei, Li Yong, Li Qing, Shi Xiaohong, Wang Jiawe. Cavernous Sinus MRI Findings in Inflammatory and Ischemic Oculomotor Cranial Nerve Palsies. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2023-09-26. PMID:37751328. |
this study explored the cavernous sinus mri findings for cavernous sinus idiopathic inflammation (inflammation group), microvascular ischemic ocn palsy (ischemic group), and ocular myasthenia gravis (omg group) patients. |
2023-09-26 |
2023-10-07 |
Not clear |
| Neşe Çelebisoy, Asim Orujov, Fidan Balayeva, Hüseyin Nezih Özdemir, Ayşın Kısabay Ak, Figen Gökça. Prognostic predictors of remission in ocular myasthenia gravis. Acta neurologica Belgica. vol 123. issue 5. 2023-09-16. PMID:36474006. |
ocular myasthenia gravis (omg) constitutes 15% of all myasthenia gravis patients. |
2023-09-16 |
2023-10-07 |
Not clear |
| Clarissa Ern Hui Fang, Desta Bokre, Sui H Won. Clinical Characteristics Associated With Secondary Generalization in Ocular Myasthenia Gravis Patients: A Systematic Review and Meta-analysis. Neurology. 2023-08-29. PMID:37643888. |
ocular myasthenia gravis (omg) is an autoimmune disorder resulting in ocular symptoms such as diplopia and ptosis. |
2023-08-29 |
2023-09-07 |
Not clear |
| Mohamad Agha, Helen Ismail, Raja Sawaya, Johnny Salame. Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: A pilot clinical trial. Muscle & nerve. 2023-06-01. PMID:37259693. |
most patients with myasthenia gravis (mg) develop ocular manifestations during their illness and up to 22% may have isolated ocular myasthenia gravis (omg). |
2023-06-01 |
2023-08-14 |
Not clear |
| Tomoko Narita, Shunya Nakane, Akiko Nagaishi, Naoya Minami, Masaaki Niino, Naoki Kawaguchi, Hiroyuki Murai, Jun-Ichi Kira, Jun Shimizu, Kazuo Iwasa, Hiroaki Yoshikawa, Yuki Hatanaka, Masahiro Sonoo, Yuko Shimizu, Hidenori Matsu. Immunotherapy for ocular myasthenia gravis: an observational study in Japan. Therapeutic advances in neurological disorders. vol 16. 2023-04-13. PMID:37051222. |
treatment for ocular myasthenia gravis (omg) has not yet been well established. |
2023-04-13 |
2023-08-14 |
Not clear |
| Montana Supawongwattana, Kavin Vanikieti, Panitha Jindahra, Tanyatuth Padungkiatsagu. Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma. Clinical ophthalmology (Auckland, N.Z.). vol 17. 2023-03-06. PMID:36875532. |
to evaluate the association in acetylcholine receptor (achr) antibody-positive ocular myasthenia gravis (omg) subjects between achr antibody titers and conversion to generalized myasthenia gravis (gmg), the presence of thyroid autoimmune antibodies, and the presence of thymoma. |
2023-03-06 |
2023-08-14 |
human |
| Parinee Kemchoknatee, Anyarak Armornpetchsathaporn, Duanghathai Tangon, Thansit Srisombu. Age of onset and factors affecting treatment responses in ocular myasthenia gravis. International ophthalmology. 2023-03-06. PMID:36879110. |
ocular myasthenia gravis (omg) is an autoimmune disease which causes ptosis, diplopia, or both. |
2023-03-06 |
2023-08-14 |
Not clear |
| Raed Behbehan. Ocular Myasthenia Gravis: A Current Overview. Eye and brain. vol 15. 2023-02-13. PMID:36778719. |
ocular myasthenia gravis (omg) is a neuromuscular disease characterized by autoantibody production against post-synaptic proteins in the neuromuscular junction. |
2023-02-13 |
2023-08-14 |
Not clear |
| Do-Hyung Kim, Hyeon Cheol Roh, Shin Yeop O. Ophthalmologic clinical features of ocular myasthenia gravis. Medicine. vol 102. issue 2. 2023-01-13. PMID:36637960. |
to investigate the clinical features of ocular myasthenia gravis (omg) in ophthalmology. |
2023-01-13 |
2023-08-14 |
Not clear |
| Zhuajin Bi, Yayun Cao, Mengcui Gui, Jing Lin, Qing Zhang, Yue Li, Suqiong Ji, Bitao B. Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2022-12-05. PMID:36469201. |
to explore the factors and risk mapping model of progression from ocular myasthenia gravis (omg) to generalized myasthenia gravis (gmg) in adult-onset patients. |
2022-12-05 |
2023-08-14 |
Not clear |
| Clarissa E H Fang, Desta Bokre, Sui H Won. Clinical characteristics of ocular myasthenia gravis and outcomes of secondary generalisation: a systematic review protocol. BMJ open. vol 12. issue 9. 2022-09-20. PMID:36127086. |
we aim to systematically assess the clinical characteristics of ocular myasthenia gravis (omg) and report on the proportion of patients who develop secondary generalised myasthenia gravis (sgmg). |
2022-09-20 |
2023-08-14 |
Not clear |
| Antoine Guéguen, Benoit Hijazi, Kevin Zuber, Romain Deschamps, Cedric Lamirel, Catherine Vignal-Clermont, Olivier Gou. Generalization of ocular myasthenia gravis 10 years after onset. Journal of neurology. 2022-08-24. PMID:36001142. |
generalization of ocular myasthenia gravis (omg) represents a pejorative evolution, and no validated generalization-prevention strategy exists. |
2022-08-24 |
2023-08-14 |
Not clear |
| Jinwei Zhang, Zeyang Zhang, Hui Zhang, Yuantao Cui, Yuan Chen, Peng Lv, Peng Zhan. Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis. Orphanet journal of rare diseases. vol 17. issue 1. 2022-08-09. PMID:35945595. |
several retrospective studies have identified risk factors associated with ocular myasthenia gravis (omg) generalization in non-surgical patients. |
2022-08-09 |
2023-08-14 |
Not clear |
| Zhe Ruan, Chao Sun, Yanlin Lang, Feng Gao, Rongjing Guo, Quan Xu, Liping Yu, Songdi Wu, Tao Lei, Yu Liu, Min Zhang, Huanhuan Li, Yonglan Tang, Ting Gao, Yanwu Gao, Xiaodan Lu, Zhuyi Li, Ting Chan. Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis. Frontiers in immunology. vol 13. 2022-07-25. PMID:35874731. |
this study aims to develop and validate a nomogram for predicting 1- and 2-year generalization probabilities in patients with ocular myasthenia gravis (omg). |
2022-07-25 |
2023-08-14 |
Not clear |
| Xian-Peng Xu, Yan-Bing Jiang, Li-Hua Guan, Qing-Jie Ji, Ying Ji. [Acupuncture combined with western medication for ocular myasthenia gravis: a randomized controlled trial]. Zhongguo zhen jiu = Chinese acupuncture & moxibustion. vol 42. issue 7. 2022-07-06. PMID:35793884. |
to compare the clinical efficacy between acupuncture combined with western medication and simple western medication for ocular myasthenia gravis (omg), and to explore its possible mechanism. |
2022-07-06 |
2023-08-14 |
Not clear |
| Jie Rao, Siyu Li, Qiyu Wang, Qi Cheng, Yu Ji, Wenwen Fu, Hui Huang, Ling Shi, Xiaorong W. Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis. Frontiers in medicine. vol 9. 2022-06-27. PMID:35755064. |
this study aims to discuss the function mechanism of regulatory t cells and its subsets in the pathogenic process of myasthenia gravis by contracting the activation levels of those cells in peripheral blood among healthy people, patients with ocular myasthenia gravis (omg) and patients with generalized myasthenia gravis (gmg). |
2022-06-27 |
2023-08-14 |
Not clear |
| Zhe Ruan, Rongjing Guo, Hongyu Zhou, Feng Gao, Ye Lin, Quan Xu, Liping Yu, Songdi Wu, Tao Lei, Min Zhang, Yanwu Gao, Xiaodan Lu, Huanhuan Li, Chao Sun, Baoli Tang, Zhuyi Li, Ting Chan. Association of immunosuppression treatment with generalization among patients with ocular myasthenia gravis: a propensity score analysis. European journal of neurology. 2022-02-21. PMID:35188698. |
to analyze disease generalization in patients with ocular myasthenia gravis (omg) treated with immunosuppression compared with patients without immunosuppression treatment. |
2022-02-21 |
2023-08-13 |
Not clear |
| Mingxia Li, Fangfang Ge, Rongjing Guo, Zhe Ruan, Yanwu Gao, Chunxiao Niu, Hong Lin, Zhengwei Zhao, Yongan Zhou, Zhuyi Li, Ting Chan. Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis. Therapeutic advances in neurological disorders. vol 12. 2022-02-17. PMID:35173803. |
the majority of ocular myasthenia gravis (omg) patients will progress to generalized myasthenia gravis (gmg), usually within 2 years of disease onset. |
2022-02-17 |
2023-08-13 |
Not clear |
| Thanchat Jienmaneechotchai, Supanut Apinyawasisuk, Supharat Jariyakosol, Parima Hirunwiwatku. Interobserver and Intra-Observer Reliability of Eyelid Tests for Ocular Myasthenia Gravis. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 2021-12-07. PMID:34860746. |
lid fatigability test (lft), cogan lid twitch (clt), and forced eyelids closure test (fect) are simple clinical screening tests for ocular myasthenia gravis (omg). |
2021-12-07 |
2023-08-13 |
Not clear |
| In Young Chung, Shivanand J Sheth, Kristen K Wells, Thomas G Campbel. The Usefulness of Anti-acetylcholine Receptor Binding Antibody Testing in Diagnosing Ocular Myasthenia Gravis. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. vol 41. issue 4. 2021-11-18. PMID:32868574. |
despite the test's high sensitivity (85%-90%) for generalized myasthenia gravis, achr-abs testing has been reported to have a low sensitivity 44%-66% for ocular myasthenia gravis (omg). |
2021-11-18 |
2023-08-13 |
Not clear |